Population Pharmacokinetic Analysis of Sparsentan in Healthy Volunteers and Patients with Focal Segmental Glomerulosclerosis

Sparsentan Clinical Trials in Glomerular Diseases: Defining Endpoints and a Path Forward in Light of the Parasol Initiative

Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety

Implications of Complete Proteinuria Remission at Any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial

Sparsentan. Dual Angiotensin II AT1 Receptor Blocker and Endothelin ETA Receptor Antagonist, Treatment of Focal Segmental Glomerulosclerosis, Treatment of IgA Nephropathy

DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS

Efficacy and Safety of Sparsentan Compared with Irbesartan in Patients with Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)